Literature DB >> 18299936

Discordant histology of primary appendiceal adenocarcinoid neoplasms with peritoneal dissemination.

Tristan D Yan1, Erwin A Brun, Paul H Sugarbaker.   

Abstract

BACKGROUND: Adenocarcinoid is a rare appendiceal tumor that shows histologically both epithelial and neuroendocrine components. We observed that some patients have peritoneal dissemination, which shows adenocarcinoma but lacks the neuroendocrine histology. The objective of the present study was to quantitate these discordant histopathological findings and examine its clinical implication.
METHODS: Twenty-six patients with peritoneal dissemination from primary appendiceal adenocarcinoid tumors underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy. All resected specimens were individually submitted for histopathological examination and immunostaining with three neuroendocrine markers. The anatomic locations for peritoneal implants were prospectively recorded. The loss of the neuroendocrine tumor type in peritoneal implants was referred to as discordant feature of the adenocarcinoid tumor. Clinical and histopathological prognostic factors for survival were analyzed.
RESULTS: In nine of the 26 patients (35%) with a primary adenocarcinoid of the appendix, a loss of the neuroendocrine immunochemical marker was noted in peritoneal implants. Discordant histology between the primary appendiceal adenocarcinoid and the peritoneal implants was statistically significantly associated with an improved survival (p = 0.0262), when patients were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
CONCLUSIONS: Discordant histology of the primary appendiceal tumor as compared to the peritoneal lesions occurs frequently in patients with adenocarcinoid. An assessment of neuroendocrine markers in both primary and peritoneal lesions may help in the clinical assessment of this group of patients. Small numbers of patients were available for this study and the conclusions are therefore limited.

Entities:  

Mesh:

Year:  2008        PMID: 18299936     DOI: 10.1245/s10434-007-9754-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology.

Authors:  Ayaz Ahmed Memon; Chintamani Godbole; Tom Cecil; Sanjeev Dayal; Brendan Moran; Alexios Tzivanakis; Faheez Mohamed; Norman J Carr
Journal:  Ann Surg Oncol       Date:  2021-11-03       Impact factor: 5.344

Review 2.  Goblet cell carcinoids of the appendix: Tumor biology, mutations and management strategies.

Authors:  Santosh Shenoy
Journal:  World J Gastrointest Surg       Date:  2016-10-27

3.  Synchronous primary neuroendocrine and mucinous epithelial tumors present in the same appendix. Case report of 2 patients.

Authors:  Paul H Sugarbaker; Almog Ben-Yaacov; David Hazzan; Aviram Nissan
Journal:  Int J Surg Case Rep       Date:  2020-01-26

4.  Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry.

Authors:  Kieran Palmer; Scott Weerasuriya; Kandiah Chandrakumaran; Brian Rous; Benjamin E White; Sangeeta Paisey; Rajaventhan Srirajaskanthan; John K Ramage
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

Review 5.  Appendiceal mixed adenoneuroendocrine carcinomas, a rare entity that can present as a Krukenberg tumor: case report and review of the literature.

Authors:  Margarita Romeo; Ariadna Quer; Antoni Tarrats; Carlos Molina; Joaquim Radua; José-Luís Manzano
Journal:  World J Surg Oncol       Date:  2015-11-26       Impact factor: 2.754

6.  Goblet cell carcinomas of the appendix: rare but aggressive neoplasms with challenging management.

Authors:  Ashley K Clift; Oskar Kornasiewicz; Panagiotis Drymousis; Omar Faiz; Harpreet S Wasan; James M Kinross; Thomas Cecil; Andrea Frilling
Journal:  Endocr Connect       Date:  2018-01-15       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.